Antifungal Treatment Advances

Why are new antifungal treatments needed?

Serious fungal infections pose particular problems for people whose immune defenses are weakened by cancer treatment, transplantation, or other illnesses. A review published in Frontiers in Cellular and Infection Microbiology on October 1, 2025, examines how resistance and the limitations of existing medicines are driving antifungal research. It brings together evidence on treatment strategies; it does not report a newly completed clinical trial. [Frontiers review](https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2025.1676009/full)

The World Health Organization’s first antifungal pipeline assessment illustrates the development challenge. Using data through September 30, 2024, it identified nine novel agents in clinical development and 22 products at the preclinical stage. These are historical pipeline counts, rather than a live inventory of September 2026 development. WHO also identified shortages of accessible diagnostic tests and pediatric treatment research. The implication is that better medicines must be accompanied by better ways to identify infections and determine which treatment is likely to work. [WHO pipeline assessment](https://www.who.int/observatories/global-observatory-on-health-research-and-development/monitoring/antifungal-agents-in-development), [WHO diagnostic and treatment findings](https://www.who.int/news/item/01-04-2025-who-issues-its-first-ever-reports-on-tests-and-treatments-for-fungal-infections)

What does rezafungin add to treatment for invasive candidiasis?

Rezafungin, marketed as Rezzayo, belongs to the echinocandin class, which disrupts fungal cell-wall production. Its July 2026 FDA labeling includes adults and children aged 12 and older when treatment alternatives are limited or unavailable. The adolescent indication relies on adult studies and analyses predicting drug exposure; the label states that no pediatric clinical studies were conducted. [FDA prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217417s007lbl.pdf)

The pivotal ReSTORE trial, published in The Lancet in 2023, randomized 199 adults to rezafungin or a comparator regimen beginning with caspofungin. Among participants in the primary efficacy analysis, approximately 59% receiving rezafungin and 61% receiving caspofungin met the combined cure endpoint at day 14. Rezafungin met the trial’s prespecified noninferiority criteria, meaning the results excluded a disadvantage larger than the chosen margin. They did not demonstrate superior cure rates or survival. The study was funded by Cidara Therapeutics and Mundipharma. [ReSTORE trial](https://doi.org/10.1016/S0140-6736(22)02324-8)

Weekly administration reduces infusion frequency, but patients still require clinical monitoring. The FDA label warns about serious allergic reactions, infusion reactions, sunlight sensitivity, and liver abnormalities. It also states that safety beyond four weekly doses has not been established. [FDA prescribing information](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217417s007lbl.pdf)

Can emerging antifungal therapies overcome drug resistance?

The Frontiers review describes approaches including drugs aimed at additional fungal targets, combinations with complementary mechanisms, and delivery systems intended to improve drug penetration. Gene-editing tools can help researchers identify fungal vulnerabilities, while nanoparticles may help transport medicines to difficult infection sites. These approaches sit at different stages of development. Laboratory activity alone cannot establish that a treatment improves survival, avoids toxicity, or reaches an effective concentration in a patient. [Frontiers review](https://www.frontiersin.org/journals/cellular-and-infection-microbiology/articles/10.3389/fcimb.2025.1676009/full)

For Candida auris, CDC guidance shows why selecting treatment remains a practical challenge. Echinocandins are recommended as initial therapy for adult clinical infections, but resistant strains occur, and susceptibility testing is needed to guide care. A positive screening swab can indicate colonization—carrying the organism without illness—and does not by itself justify antifungal treatment. Accurate identification, specialist assessment, and infection-control measures therefore remain essential alongside drug development. [CDC clinical overview](https://www.cdc.gov/candida-auris/hcp/clinical-overview/index.html)